Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test. The latest ...

As an ambassador for Myriad's Breast Cancer Risk Assessment Program, Storm will promote the MyRisk® with RiskScore® Hereditary Cancer Test, which evaluates genetic risks for various cancers.

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test, the first and ...

Myriad Genetics Inc. (MYGN) announced an agreement with Hannah Storm, a nationally renowned sports broadcaster, who recently revealed ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...